What is the level of liabilities of Vaxcyte this year?
Vaxcyte has a debt balance of 167.45 M USD this year.
Vaxcyte Liabilities 2024
Vaxcyte Liabilities
167.45 M USD
Ticker
PCVX
ISIN
US92243G1085
WKN
A2P6R6
In 2024, Vaxcyte's total liabilities amounted to 167.45 M USD, a 218.34% difference from the 52.6 M USD total liabilities in the previous year.
Vaxcyte Aktienanalyse
What does Vaxcyte do?
Vaxcyte Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of vaccines for various diseases. The company was founded in 2018 and is headquartered in Foster City, California. Vaxcyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Vaxcyte's Liabilities
Vaxcyte's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Vaxcyte's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Vaxcyte's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Vaxcyte's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Vaxcyte’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Vaxcyte stock
What were the liabilities of Vaxcyte compared to the previous year?
The liabilities of Vaxcyte have increased by 218.34% increased compared to the previous year.
What are the consequences of high debt for investors of Vaxcyte?
High liabilities can pose a risk for investors of Vaxcyte, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Vaxcyte?
Low liabilities mean that Vaxcyte has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Vaxcyte affect the company?
An increase in liabilities of Vaxcyte can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Vaxcyte affect the company?
A decrease in the liabilities of Vaxcyte can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Vaxcyte?
Some factors that can influence the liabilities of Vaxcyte include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Vaxcyte so important for investors?
The liabilities of Vaxcyte are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Vaxcyte take to modify the liabilities?
To change its liabilities, Vaxcyte can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Vaxcyte pay?
Over the past 12 months, Vaxcyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vaxcyte is expected to pay a dividend of 0 USD.
What is the dividend yield of Vaxcyte?
The current dividend yield of Vaxcyte is .
When does Vaxcyte pay dividends?
Vaxcyte pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Vaxcyte?
Vaxcyte paid dividends every year for the past 0 years.
What is the dividend of Vaxcyte?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Vaxcyte located?
Vaxcyte is assigned to the 'Health' sector.
Wann musste ich die Aktien von Vaxcyte kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Vaxcyte from 10/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/11/2024.
When did Vaxcyte pay the last dividend?
The last dividend was paid out on 10/11/2024.
What was the dividend of Vaxcyte in the year 2023?
In the year 2023, Vaxcyte distributed 0 USD as dividends.
In which currency does Vaxcyte pay out the dividend?
The dividends of Vaxcyte are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Vaxcyte
Our stock analysis for Vaxcyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vaxcyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
